[{"indications": "Indications\u00a0\n(From Vancomycin and teicoplanin: British National Formulary)\nVancomycin and teicoplanin and under\r\nDose", "name": "TEICOPLANIN", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "5 Infections", "5.1 Antibacterial drugs", "5.1.7 Some other antibacterials", "Vancomycin and teicoplanin"], "cautions": "Cautions\u00a0vancomycin sensitivity; blood counts and liver and kidney function tests required; monitor renal and auditory function during prolonged\r\ntreatment in renal impairment or if other nephrotoxic or neurotoxic\r\ndrugs given; monitor plasma-teicoplanin concentration during parenteral\r\ntreatment if severe sepsis or burns, deep-seated staphylococcal infection\r\n(including bone and joint infection), endocarditis, renal impairment,\r\nin elderly, and in intravenous drug abusers; interactions: Appendix 1 (teicoplanin)", "side-effects": "Side-effects\u00a0rash, pruritus; less commonly nausea, vomiting, diarrhoea, bronchospasm, dizziness, headache,\r\nfever, leucopenia, thrombocytopenia, eosinophilia, tinnitus, mild\r\nhearing loss, vestibular disorders, thrombophlebitis; also\r\nreported renal failure, exfoliative dermatitis, Stevens-Johnson\r\nsyndrome, toxic epidermal necrolysis", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/3878.htm", "doses": ["By mouth, Clostridium difficile infection, 200\u00a0mg twice daily for 10 days", "By intravenous injection or infusion, adult body-weight\r\nunder 70\u00a0kg, initially 400\u00a0mg every 12 hours for 3 doses, subsequently\r\n400\u00a0mg once daily (subsequent doses can alternatively be given by intramuscular injection); body-weight over 70\u00a0kg, initially\r\n6\u00a0mg/kg every 12 hours for 3 doses, then 6\u00a0mg/kg once daily; higher\r\ndoses may be required in severe infection (including burns, septicaemia,\r\nseptic arthritis, and osteomyelitis), consult product literature", "Streptococcal endocarditis (in combination with another antibacterial\r\nif necessary, see Table 1, section 5.1), by intravenous\r\ninjection or infusion, adult initially 6\u00a0mg/kg every 12 hours for 3 doses,\r\nthen 6\u00a0mg/kg once daily", "Enterococcal endocarditis (in combination with another antibacterial,\r\nsee Table 1, section 5.1), by intravenous\r\ninjection or infusion, adult initially 10\u00a0mg/kg every 12 hours for 3 doses,\r\nthen 10\u00a0mg/kg once daily", "Surgical prophylaxis, adult, by intravenous injection, 400\u00a0mg up to 30 minutes before\r\nthe procedure; open fractures, by intravenous infusion, 800\u00a0mg up to 30 minutes before skeletal stabilisation and definitive\r\nsoft-tissue closure", "child under 18 years see BNF for Children", "Plasma-teicoplanin concentration is not measured\r\nroutinely because a relationship between plasma concentration and\r\ntoxicity has not been established. However, the plasma-teicoplanin\r\nconcentration can be used to optimise parenteral treatment in some\r\npatients (see Cautions). Pre-dose (\u2018trough\u2019) concentrations should\r\nbe greater than 10\u00a0mg/litre (greater than 15\u201320\u00a0mg/litre in endocarditis;\r\ngreater than 20\u00a0mg/litre in deep-seated infection such as bone and\r\njoint infection), but less than 60\u00a0mg/litre. Teicoplanin doses in\r\nBNF may differ from those in product literature"], "pregnancy": "Pregnancy\u00a0manufacturer advises use only if potential benefit\r\noutweighs risk"}]